Citi raised the firm’s price target on Edwards Lifesciences (EW) to $96 from $95 and keeps a Buy rating on the shares. The company reported a Q3 beat with an increased revenue outlook, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $99 from $95 at Barclays
- Edwards Lifesciences Reports Strong Q3 2025 Growth
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Edwards Lifesciences Announces CFO Transition Plan
- Edwards Lifesciences CFO Ullem to transition from role by mid-2026